Nothing Special   »   [go: up one dir, main page]

Schrag et al., 2019 - Google Patents

Binding symmetry and surface flexibility mediate antibody self-association

Schrag et al., 2019

View PDF @Full View
Document ID
12466458734760231107
Author
Schrag J
Picard M
Gaudreault F
Gagnon L
Baardsnes J
Manenda M
Sheff J
Deprez C
Baptista C
Hogues H
Kelly J
Purisima E
Shi R
Sulea T
Publication year
Publication venue
MAbs

External Links

Snippet

Solution stability is an important factor in the optimization of engineered biotherapeutic candidates such as monoclonal antibodies because of its possible effects on manufacturability, pharmacology, efficacy and safety. A detailed atomic understanding of the …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/16—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions

Similar Documents

Publication Publication Date Title
Bailly et al. Predicting antibody developability profiles through early stage discovery screening
US9988460B2 (en) Crystal structures of heterodimeric Fc domains
Dobson et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
Baran et al. Principles for computational design of binding antibodies
Peng et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
Majumdar et al. Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody
Sulea et al. Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment
Lee et al. Toward aggregation-resistant antibodies by design
Zhang et al. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity
Geoghegan et al. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering
Sawant et al. Toward drug-like multispecific antibodies by design
Gil-Garcia et al. Combining structural aggregation propensity and stability predictions to redesign protein solubility
Buck et al. Computational methods to predict therapeutic protein aggregation
Jones et al. Complementary MS methods assist conformational characterization of antibodies with altered S–S bonding networks
Schrag et al. Binding symmetry and surface flexibility mediate antibody self-association
CA2889951A1 (en) Crystal structures of heterodimeric fc domains
Ebo et al. An in vivo platform to select and evolve aggregation-resistant proteins
Lerch et al. Infliximab crystal structures reveal insights into self-association
Makowski et al. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning
Sakhnini et al. Improving the developability of an antigen binding fragment by aspartate substitutions
Froning et al. Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Tennenhouse et al. Computational optimization of antibody humanness and stability by systematic energy-based ranking
Svilenov et al. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties
Licari et al. Embedding dynamics in intrinsic physicochemical profiles of market-stage antibody-based biotherapeutics
O'Brien et al. Biophysical characterization and molecular simulation of electrostatically driven self‐association of a single‐chain antibody